Gilead Sciences (GILD) Set to Acquire Arcellx

robot
Abstract generation in progress

Gilead Sciences (NASDAQ: GILD) has announced the attainment of all regulatory approvals for its acquisition of Arcellx and has extended the tender offer for Arcellx’s common stock. This news follows a positive rating update from Truist, which raised Gilead’s price target to $155 from $152, maintaining a Buy rating. The biotech firm is also preparing for the launch of Yeztugo and updating on anito-cel, anticipating continued deal activity in the biotech sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin